Epizyme

OverviewSuggest Edit

Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

TypePublic
Founded2007
HQCambridge, MA, US
Websiteepizyme.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Feb 2020)203(+64%)
Job Openings19
Revenue (FY, 2020)$15.8 M(-33%)
Share Price (May 2022)$0.5(-3%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Epizyme

David M Mott

David M Mott

Chairman
Grant Bogle

Grant Bogle

President, Chief Executive Officer
Matthew Ros

Matthew Ros

Executive Vice President, Chief Strategy and Business Officer
Joseph Beaulieu

Joseph Beaulieu

Senior Vice President, Head of Finance
John Weidenbruch

John Weidenbruch

Senior Vice President, General Counsel
Jeffery Kutok

Jeffery Kutok

Chief Scientific Officer
Show more

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, MA, US (HQ)
400 Technology Square, 400 Technology Square
Show all (1)

Epizyme Financials and Metrics

Epizyme Revenue

Epizyme's revenue was reported to be $15.76 m in FY, 2020
USD

Revenue (Q1, 2021)

7.6m

Gross profit (Q1, 2021)

4.8m

Gross profit margin (Q1, 2021), %

62.6%

Net income (Q1, 2021)

(70.3m)

EBIT (Q1, 2021)

(64.3m)

Market capitalization (13-May-2022)

54.1m

Closing stock price (13-May-2022)

0.5

Cash (31-Mar-2021)

73.7m

EV

215.2m
Epizyme's current market capitalization is $54.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

21.7m23.8m15.8m

Revenue growth, %

(40%)(94%)213%

Cost of goods sold

5.1m

Gross profit

10.7m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

12.0m7.9m5.9m5.7m1.4m2.5m3.6m7.6m

Cost of goods sold

614.0k1.0m1.6m2.9m

Gross profit

740.0k1.4m2.0m4.8m

Gross profit Margin, %

55%59%55%63%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

123.6m190.1m208.3m77.9m226.7m86.7m139.5m168.2m

Accounts Receivable

33.7m2.1m262.0k23.0k382.0k20.1m2.6m3.1m

Prepaid Expenses

2.4m2.8m4.5m9.0m12.2m15.5m17.9m

Inventories

6.5m10.5m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

148.7m139.6m237.1m229.9m211.7m244.5m236.7m229.9m312.7m89.5m66.0m64.4m88.5m219.8m130.3m67.9m66.3m144.3m45.9m93.5m179.3m117.2m93.4m73.7m

Accounts Receivable

7.8m2.2m8.2m2.2m2.1m365.0k723.0k177.0k176.0k60.0k6.2m8.0k25.0k25.0k24.0k12.3m13.0m13.3m12.0m1.6m1.7m4.6m9.8m

Prepaid Expenses

2.0m2.1m2.1m2.7m3.3m2.5m2.0m2.5m5.5m7.9m5.5m8.8m8.6m10.0m8.9m8.5m7.0m15.2m14.1m16.1m22.6m21.0m18.5m16.9m

Inventories

1.7m9.9m8.2m14.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.5m)(55.0m)(132.4m)(110.2m)(134.3m)(123.6m)(170.3m)(231.7m)

Depreciation and Amortization

703.0k742.0k1.4m1.6m1.6m1.1m4.0m

Inventories

(10.5m)

Accounts Payable

1.6m3.6m(3.6m)341.0k2.0m(2.4m)3.4m1.5m
USDQ2, 2013

Financial Leverage

1.7 x
Show all financial metrics

Epizyme Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Epizyme Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Epizyme Online and Social Media Presence

Embed Graph

Epizyme News and Updates

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio

Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?

NEW YORK, May 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AMC, EVFM, NOK, and ARQT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug

Shares of Epizyme Inc. were up 11.0% in premarket trading on Friday after SVB Leerink upgraded the company's stock to outperform, from market perform, citing Tazverik's potential opportunity in the follicular lymphoma market. Analyst Andrew Berens told investors that the drug's potential as a "main…
Show more

Epizyme Blogs

Epizyme To Participate in H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2022-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle , President and Chief

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

TAZVERIK® (tazemetostat) Net Product Revenue of $ 8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study Assessing

Epizyme Announces Date of First Quarter 2022 Financial Results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme’s Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R 2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2022-- Epizyme (Nasdaq: EPZM), a fully

Epizyme to Participate in Upcoming Healthcare Conferences in March

Epizyme to Participate in Upcoming Healthcare Conferences in March Content Import Wed, 03/02/2022 - 08:03 Epizyme to Participate in Upcoming Healthcare Conferences in March Mar 02, 2022 This release is a backfill from a News Wire General …

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into 3Q 2023 Company Engaged in Global Start-up
Show more

Epizyme Frequently Asked Questions

  • When was Epizyme founded?

    Epizyme was founded in 2007.

  • Who are Epizyme key executives?

    Epizyme's key executives are David M Mott, Grant Bogle and Matthew Ros.

  • How many employees does Epizyme have?

    Epizyme has 203 employees.

  • What is Epizyme revenue?

    Latest Epizyme annual revenue is $15.8 m.

  • What is Epizyme revenue per employee?

    Latest Epizyme revenue per employee is $77.6 k.

  • Who are Epizyme competitors?

    Competitors of Epizyme include Imago BioSciences, Italfarmaco and Ascentage Pharma.

  • Where is Epizyme headquarters?

    Epizyme headquarters is located at 400 Technology Square, 400 Technology Square, Cambridge.

  • Where are Epizyme offices?

    Epizyme has an office in Cambridge.

  • How many offices does Epizyme have?

    Epizyme has 1 office.